Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib
In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.
Medicine performance-enhancing company, Nanoform, announced in an Oct. 14, 2025 press release that it has established a new company through a collaboration with Belgian pharmaceutical group, A.forall, and Portuguese fund management company, IMGA Futurum Tech Fund (1). The aim of BRAFMed Ltd is to progress the clinical development and future outlicensing of Nanoencorafenib, which is a patient-centric nanoformulation of encorafenib.
Encorafenib is an oral anti-cancer medication, marketed by Pfizer under the brand name Braftovi that has a current dosing regimen of up to six 75 mg capsules to be taken each day. Nanoform has developed a prototype nanoformulation of the drug that improves the dosing by increasing the drug load.
“Nanoform’s performance-enhancing technologies play a significant part in the development of new and improved medicines, and we are proud today to announce partnering the clinical development and commercialization of Nanoencorafenib, which is one of our innovative development initiatives,” said Prof. Edward Hæggström, CEO of Nanoform, in a company press release (1). “This announcement underscores investors’ and industry players’ confidence in our technologies and we are pleased to welcome these highly experienced partners to drive this improved product forward.”
“Our mission is to develop medicines that make a meaningful difference for patients,” added Steen Vangsgaard, CEO of A.forall, in the press release (1). “By combining our skills in development, registration, and commercialization with Nanoform’s pioneering technology and unique medicines such as nanoencorafenib, we can offer treatments that improve care and outcomes. Together, we’re committed to giving patients hope and better health through innovation.”
“IMGA is proud to support the development of Nanoencorafenib alongside Nanoform and A.forall. We believe that Nanoform’s advanced nanoforming technology represents a significant leap forward in patient-centric drug innovation. By enabling higher drug loads and more convenient dosing, this technology has the potential to transform treatment experiences and outcomes for patients. Our investment reflects our commitment to fostering breakthrough solutions in healthcare and bringing meaningful improvements to those who need them most,” commented Tiago Geraldes, Private Equity Director at IMGA.
A letter of intent to establish BRAFMed was signed by Nanoform, in collaboration with A.forall and IMGA, in May 2025. After incorporation, BRAFMed is expected to be a wholly owned subsidiary of Nanoform and once total investment has been received, Nanoform’s fully diluted ownership of BRAFMed is expected to be between 40% and 50% (2).
References
Nanoform. Nanoform Outlicenses Nanoencorafenib and Signs Development and Commercialization Agreement with A.forall and IMGA. Press Release, Oct. 14, 2025.
Nanoform. Inside Information Made Public: Nanoform Partners with Two Specialist Healthcare Investors to Develop and Commercialize Nanoencorafenib. Press Release, May 20, 2025.